Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580723 · ClinicalTrials.gov registry record · Phase 1
Effects of PRK 124 Lotion in Acne Rosacea
A Phase 1 study of Acne Rosacea, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00580723 is a Phase 1 study of Acne Rosacea that has completed, run by University of California, Irvine. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00580723, a Phase 1 study of Acne Rosacea, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.
Conditions Studied
Interventions
- OTHER PRK 124
Study Locations (1)
California
- UC Irvine Dermatology Clinical Research Center - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580723
The ClinicalTrials.gov registry entry for NCT00580723 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Rosacea appearing as the primary indexed condition, and to 1 intervention - of which PRK 124 is the first listed.
NCT00580723 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00580723 about?
NCT00580723 is a clinical study titled "Effects of PRK 124 Lotion in Acne Rosacea". The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.
What is the current status of trial NCT00580723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-04. Estimated completion is 2009-02.
What conditions does trial NCT00580723 study?
This clinical trial studies the following conditions: Acne Rosacea.
What interventions are being tested in trial NCT00580723?
The interventions under investigation include: PRK 124 (OTHER).
Who is sponsoring clinical trial NCT00580723?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00580723 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.